Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases

– Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental delay –

Excerpt from the Press Release:

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae’s Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months. By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases.

Identifying and recruiting patients with rare diseases into clinical studies is difficult, making it challenging to understand the etiology, disease course, differences among subpopulations and the impact of novel treatments. The Rare Patient Network is a new approach to solving these challenges by directly engaging with the broader community of patients with rare neurodevelopmental conditions.

“The Rare Patient Network is a proactive way to empower patients,” said Terry Jo Bitchell, PhD., executive director of COMBINEDBrain. “Even before a diagnosis or without a diagnosis, families who are grappling with epilepsy or a developmental delay will have a way to help each other and themselves simply by using their own medical record as a resource. When a treatment comes along, this resource will already be there just waiting to be part of the solution.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release